文献速递MDS 与骨髓增殖性肿瘤白血病

初治骨髓增生异常综合征伴原始细胞增多患者接受去甲基化药物治疗前后基因突变状态与疗效及生存的相关性分析

[Analysis of the association between pre- and post-treatment genetic mutation status and treatment efficacy and survival in patients with newly diagnosed myelodysplastic syndromes with excess blasts receiving hypomethylating agent therapy].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2025-01-01

回顾性分析69例初治MDS-EB患者接受HMA单药治疗前后NGS基因突变与疗效及生存的关系。TP53突变状态与DOR和OS显著相关,双打击TP53突变者DOR和OS最短。非TP53突变患者中主克隆显著清除组OS优于非显著清除组。

要点

  • 治疗前DTA、信号转导、转录因子或剪接因子突变与4疗程内最佳疗效、DOR和OS无显著相关。
  • 双打击TP53突变者中位DOR 3个月、OS 16个月,均短于单打击和非TP53突变者。
  • 非TP53突变患者主克隆显著清除组中位OS 55个月,优于非显著清除组的31个月(P=0.013)。

核心结论

  • MDS-EB患者接受HMA单药治疗前,单一基因突变、IPSS-R和IPSS-M均无法有效预测治疗效果。
  • 非TP53突变患者通过NGS监测治疗过程中主克隆清除程度可能预测接受HMA治疗的MDS患者的长期疗效。

研究设计与样本

  • 回顾性分析2016年6月至2023年9月于中国医学科学院血液病医院完成至少4个疗程HMA单药治疗且治疗前完成NGS的69例初治MDS-EB患者。
  • 比较HMA治疗前后基因突变状态对疗效与预后的影响。

主要发现

  • 69例患者中男47例、女22例,中位年龄62岁(范围41~80岁),MDS-EB1 39例、MDS-EB2 30例,中位治疗6个疗程(范围4~35),中位随访22个月(范围5~72),中位OS 32个月(95%CI 27~43)。
  • 治疗前DTA突变、信号转导基因突变、转录因子突变或剪接因子突变与4个疗程内最佳疗效、DOR和OS均无显著相关性。
  • 双打击TP53突变者、单打击TP53突变者和非TP53突变者的中位DOR分别为3个月(95%CI 1~10)、10个月(95%CI 3~34)和16个月(95%CI 8~27)(P=0.032),中位OS分别为16个月(95%CI 7~38)、15个月(95%CI 6~40)和35个月(95%CI 14~91)(P<0.001)。
  • 非TP53突变患者中主克隆显著清除组(14例)和非显著清除组(10例)中位OS分别为55个月(95%CI 9~106)和31个月(95%CI 16~184)(P=0.013)。
  • HMA治疗有效且主克隆显著清除者的3年OS率为(77.8±13.9)%。

关键数值与推荐

  • 双打击TP53突变者中位DOR 3个月(95%CI 1~10),单打击者10个月(95%CI 3~34),非TP53突变者16个月(95%CI 8~27)(P=0.032)。
  • 双打击TP53突变者中位OS 16个月(95%CI 7~38),单打击者15个月(95%CI 6~40),非TP53突变者35个月(95%CI 14~91)(P<0.001)。
  • 非TP53突变患者中主克隆显著清除组中位OS 55个月(95%CI 9~106),非显著清除组31个月(95%CI 16~184)(P=0.013)。
  • IPSS-R和IPSS-M均不能预测接受HMA治疗4个疗程内最佳疗效和DOR。

临床怎么用

  • 原文未据此给出推荐。
  • 作者认为非TP53突变患者通过NGS监测治疗过程中主克隆清除程度可能预测接受HMA治疗的MDS患者的长期疗效。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To investigate the association between pre- and post-treatment gene mutation profiles and clinical outcomes (treatment response and prognosis) in patients with myelodysplastic syndromes with excess blasts (MDS-EB) receiving hypomethylating agent (HMA) monotherapy. Methods: The clinical characteristics, treatment efficacy, and survival outcomes of 69 treatment-naive patients with MDS-EB who underwent next-generation sequencing (NGS) before treatment and completed at least 4 cycles of HMA monotherapy at the Institute of Hematology & Blood Diseases Hospital, CAMS & PUMC, between June 2016 and September 2023, were retrospectively analyzed. Results: ① The cohort comprised 47 males and 22 females with a median age of 62 years (range: 41-80). Thirty-nine patients were classified as MDS-EB1 and 30 as MDS-EB2. The median number of treatment cycles was 6 (range: 4-35). The median follow-up duration was 22 months (range: 5-72), and the median overall survival (OS) was 32 months (95% CI: 27-43). ② The presence of DTA (DNMT3A, TET2, or ASXL1) mutations, signaling pathway mutations, transcription factor mutations, or splicing factor mutations before HMA treatment showed no significant association with the best response within 4 treatment cycles, duration of response (DOR), or OS. TP53 mutation status was significantly associated with DOR and shorter OS. The median DOR was 3 months (95% CI: 1-10) for patients with biallelic TP53 mutations, 10 months (95% CI: 3-34) for those with monoallelic TP53 mutations, and 16 months (95% CI: 8-27) in patients without TP53 mutations (P=0.032). The median OS was 16 months (95% CI: 7-38), 15 months (95% CI: 6-40), and 35 months (95% CI: 14-91), respectively (P<0.001). ③ Neither the Revised International Prognostic Scoring System (IPSS-R) nor the Molecular International Prognostic Scoring System (IPSS-M) could predict the best response within 4 treatment cycles or DOR in patients receiving HMA therapy. ④ Among patients without TP53 mutations, the median OS was 55 months (95% CI: 9-106) for the major clone significant clearance group (n=14) and 31 months (95% CI: 16-184) for the major clone non-significant clearance group (n=10) (P=0.013). For patients who responded to HMA treatment and had significant major clone clearance, the 3-year OS rate reached (77.8±13.9) %. Conclusion: For MDS-EB patients receiving HMA monotherapy, single gene mutations, IPSS-R, and IPSS-M could not effectively predict treatment outcomes before therapy. However, for patients without TP53 mutations, monitoring the degree of major clone clearance by NGS during treatment may predict the long-term efficacy in MDS patients receiving HMA therapy. 目的: 探索接受去甲基化药物(HMA)单药治疗的骨髓增生异常综合征伴原始细胞增多(MDS-EB)患者治疗前后基因突变状态与疗效及预后的关系。 方法: 2016年6月至2023年9月于中国医学科学院血液病医院完成了至少4个疗程HMA单药治疗且治疗前进行了二代测序(NGS)的69例初治MDS-EB患者,回顾性分析其临床特征、疗效、生存时间以及生存情况。比较HMA治疗前后基因突变症状对疗效与预后的影响。 结果: ①69例患者中,男47例,女22例,中位年龄62(41~80)岁。MDS-EB1 39例,MDS-EB2 30例,中位治疗6(4~35)个疗程。中位随访22(5~72)个月,中位生存期32(95%CI:27~43)个月。②HMA治疗前是否伴有DTA(DNMT3A、TET2和ASXL1)突变、信号转导基因突变、转录因子突变或剪接因子突变与4个疗程内最佳疗效、疗效持续时间(DOR)和总生存(OS)均无显著相关性。TP53突变状态与DOR相关且OS时间显著缩短,伴有双打击TP53突变者、单打击TP53突变者和非TP53突变者的中位DOR分别为3(95%CI:1~10)、10(95%CI:3~34)和16(95%CI:8~27)个月(P=0.032),中位OS时间分别为16(95%CI:7~38)、15(95%CI:6~40)和35(95%CI:14~91)个月(P<0.001)。③修订的国际预后积分系统(IPSS-R)和含分子遗传学指标的国际预后积分系统(IPSS-M)均不能预测接受HMA治疗4个疗程内最佳疗效和DOR。④非TP53突变患者,主克隆显著清除组(14例)和主克隆非显著清除组(10例)中位OS时间分别为55(95%CI:9~106)个月和31(95%CI:16~184)个月(P=0.013)。HMA治疗有效且主克隆显著清除者的3年OS率达(77.8±13.9)%。 结论: MDS-EB患者接受HMA单药治疗前,单一基因突变、IPSS-R和IPSS-M预后积分系统均无法有效预测治疗效果。非TP53突变患者,通过NGS监测治疗过程中主克隆清除程度可预测接受HMA治疗的MDS患者的长期疗效。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Zhong T, Qin TJ, Xu ZF, et al. [Analysis of the association between pre- and post-treatment genetic mutation status and treatment efficacy and survival in patients with newly diagnosed myelodysplastic syndromes with excess blasts receiving hypomethylating agent therapy]. Zhonghua Xue Ye Xue Za Zhi. 2025. PMID: 40623900. doi:10.3760/cma.j.cn121090-20241210-00553

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。